Literature DB >> 32547847

Use of Mixed Amphetamine Salts in a Patient with Depersonalization/Derealization Disorder.

Samuel R Weber1.   

Abstract

Depersonalization and derealization symptoms are common and often transient. Recurrent, persistent symptoms can result in a diagnosis of depersonalization/derealization disorder (DDD). This is a diagnosis with little evidence available regarding effective interventions, and there are currently no pharmacological treatments for DDD approved by the United States Food and Drug Administration (FDA). Here, we reported a case of an adult female whose presentation was consistent with DDD. Her DDD symptoms notably reduced after treatment with mixed amphetamine salts. We also reviewed the limited research examining the efficacy of lamotrigine, benzodiazepines, antidepressants, naltrexone, and antipsychotics in DDD. Given the lack of evidence-based interventions for patients with DDD, additional research into the potential benefit of using psychostimulants might be warranted.
Copyright © 2020. Matrix Medical Communications. All rights reserved.

Entities:  

Keywords:  Dissociative disorders; depersonalization; derealization; psychostimulants

Year:  2020        PMID: 32547847      PMCID: PMC7239558     

Source DB:  PubMed          Journal:  Innov Clin Neurosci        ISSN: 2158-8333


  16 in total

1.  Methylphenidate in depersonalization disorder: a case report.

Authors:  Q Foguet; M J Alvárez; E Castells; F Arrufat
Journal:  Actas Esp Psiquiatr       Date:  2011-01-01       Impact factor: 1.196

2.  Cognitive-behaviour therapy for depersonalisation disorder: an open study.

Authors:  Elaine C M Hunter; Dawn Baker; Mary L Phillips; Mauricio Sierra; Anthony S David
Journal:  Behav Res Ther       Date:  2005-09

3.  Lamotrigine as an add-on treatment for depersonalization disorder: a retrospective study of 32 cases.

Authors:  Mauricio Sierra; Dawn Baker; Nicholas Medford; Emma Lawrence; Maxine Patel; Mary L Phillips; Anthony S David
Journal:  Clin Neuropharmacol       Date:  2006 Sep-Oct       Impact factor: 1.592

4.  Lamotrigine in the immediate treatment of outpatients with depersonalization disorder without psychiatric comorbidity: randomized, double-blind, placebo-controlled study.

Authors:  Nadir A Aliyev; Zafar N Aliyev
Journal:  J Clin Psychopharmacol       Date:  2011-02       Impact factor: 3.153

5.  Treatment of depersonalization disorder with clomipramine.

Authors:  D Simeon; D J Stein; E Hollander
Journal:  Biol Psychiatry       Date:  1998-08-15       Impact factor: 13.382

Review 6.  Unique and Overlapping Symptoms in Schizophrenia Spectrum and Dissociative Disorders in Relation to Models of Psychopathology: A Systematic Review.

Authors:  Selwyn B Renard; Rafaele J C Huntjens; Paul H Lysaker; Andrew Moskowitz; André Aleman; Gerdina H M Pijnenborg
Journal:  Schizophr Bull       Date:  2016-05-21       Impact factor: 9.306

7.  Fluoxetine therapy in depersonalisation disorder: randomised controlled trial.

Authors:  Daphne Simeon; Orna Guralnik; James Schmeidler; Margaret Knutelska
Journal:  Br J Psychiatry       Date:  2004-07       Impact factor: 9.319

8.  Psychotherapy and pharmacotherapy for patients with dissociative identity disorder.

Authors:  Julie P Gentile; Kristy S Dillon; Paulette Marie Gillig
Journal:  Innov Clin Neurosci       Date:  2013-02

9.  Dissociative disorders and suicidality in psychiatric outpatients.

Authors:  Brad Foote; Yvette Smolin; Deborah I Neft; Deborah Lipschitz
Journal:  J Nerv Ment Dis       Date:  2008-01       Impact factor: 2.254

Review 10.  The epidemiology of depersonalisation and derealisation. A systematic review.

Authors:  E C M Hunter; M Sierra; A S David
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2004-01       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.